Friday, November 15, 2024
HomeTagsOCEANIC

OCEANIC

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Bayer announced the start of a Phase III clinical development program “OCEANIC” to investigate the efficacy and safety of asundexian (BAY 2433334), an investigational...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics